We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations

By LabMedica International staff writers
Posted on 16 Sep 2019
Print article
Image: Circulating tumor cell-free DNA (ctDNA) is found in serum and plasma fractions from blood. The mechanism of ctDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Image: Circulating tumor cell-free DNA (ctDNA) is found in serum and plasma fractions from blood. The mechanism of ctDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Results published in a recent paper suggested that liquid biopsy – specifically analysis of cell-free tumor DNA (ctDNA) – may capture the genetic diversity of acquired drug resistance better than classical surgical biopsy of the tumor.

The effectiveness of ctDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-scale prospective cohorts of patients receiving targeted therapy. Therefore, investigators at the Broad Institute of MIT and Harvard (Boston MA, USA) and their colleagues undertook a prospective study of a cohort of 42 patients with molecularly defined gastrointestinal cancers and acquired resistance to targeted therapy.This study was included in a five-year collaboration that analyzed tumors before and after the onset of drug resistance.

Tumors were analyzed using both liquid and tissue biopsies procedures. The investigators employed a suite of computational tools developed at the Broad Institute, known as PhylogicNDT, to analyze tumor DNA and resistance mutations.

Direct comparison of ctDNA versus tumor biopsy revealed that ctDNA more frequently identified clinically relevant resistance alterations and multiple resistance mechanisms, detecting resistance alterations not found in the matched tumor biopsy in 78% of cases. Whole-exome sequencing of serial ctDNA, tumor biopsies and rapid autopsy specimens elucidated substantial geographic and evolutionary differences across separate tumors.

"This study is the largest to date to directly compare liquid biopsy to tumor biopsy in the setting of cancer resistance," said senior author Dr. Ryan Corcoran, assistant professor of medicine at Harvard Medical School. "Our findings suggest that liquid biopsy may be the preferred clinical modality for assessing how patients' tumors have evolved after they have become resistant to therapy."

The investigators proposed that the data collected in this study indicated that acquired resistance was frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in an individual patient may represent the “rule” rather than the “exception.”

The study was published in the September 9, 2019, online edition of the journal Nature Medicine.

Related Links:
Broad Institute

Gold Supplier
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit
New
Hepatitis C ELISA Test
HCV ELISA
New
Thyroglobulin (Tg) Assay
LIAISON Anti-Tg
New
Thyroid Stimulating Hormone Test
TSH Rapid Test

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.